वैकल्पिक उत्पाद विश्लेषण
आपकी अनुमति से हम गोपनीयता-सीमित विश्लेषण का उपयोग करके समझते हैं कि कौन-सी शोध यात्राएँ उपयोगी हैं। हम विज्ञापन ट्रैकर या सत्र रिकॉर्डिंग नहीं चलाते। आप यह विकल्प प्राथमिकताओं में बदल सकते हैं। पढ़ें गोपनीयता नीति.
Elevance Health Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $94.1B |
|---|
| Revenue (ttm) | 201.8B |
|---|
| Net income (ttm) | 5.1B |
|---|
| EPS (ttm) | $23.4 |
|---|
| Shares out | 216.1M |
|---|
| P/E (trailing) | 17.6x |
|---|
| P/E (forward) | 13.7x |
|---|
| Dividend | $6.88 (1.67%) |
|---|
| Volume | 858,930 |
|---|
| Beta | 0.71 |
|---|
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $138.64B | $156.60B | $171.34B | $177.01B | $199.13B | +9.5% |
| Gross profit | $35.99B | $39.95B | $47.01B | $49.24B | $50.90B | +9.1% |
| Operating income | $7.56B | $8.28B | $8.50B | $7.86B | $7.20B | -1.2% |
| Net income | $6.16B | $5.89B | $5.99B | $5.98B | $5.66B | -2.1% |
| EPS (diluted) | $24.95 | $24.28 | $25.22 | $25.68 | $25.21 | +0.3% |
| EBITDA | $10.03B | $10.13B | $10.49B | $10.48B | $9.66B | -0.9% |
| R&D | — | — | — | — | — | — |
| SG&A | $15.92B | $17.70B | $20.09B | $20.03B | $20.98B | +7.2% |
Recent company headlines from major financial publishers.
Medicare Advantage underwriting margins accelerate toward management target ranges ahead of schedule, supported by Star Rating recoveries and favorable claims development. Carelon secures major third-party external selling wins, expanding service operating margins substantially. Consolidated operating margins expand meaningfully, driving accelerated annual adjusted earnings growth with valuation multiple expansion.
Elevance executes disciplined commercial pricing resets matching low-double-digit cost inflation while state Medicaid rate adjustments gradually restore underwriting margins. Carelon continues steady 5% revenue expansion with 5.3% pharmacy operating margins. Consolidated operating margins normalize from 3.6% in 2025 to 4.2% by 2030, supporting our fair value midpoint of $474.64 (+9.33% implied upside).
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 7.4% | $513 | $525 | $538 | $553 | $570 |
| 7.9% | $483 | $493 | $504 | $516 | $529 |
| 8.4% | $458 | $466 | $475 | $484 | $495 |
| 8.9% | $436 | $442 | $450 | $458 | $466 |
| 9.4% | $416 | $422 | $428 | $435 | $442 |
Upcoming earnings date and setup when available.
हर महीने प्रकाशित शोध संस्करण की रेटिंग। रेटिंग विश्लेषण की तारीख की कीमत की तुलना उचित मूल्य से करती है; यह इस बात का रिकॉर्ड नहीं है कि आकलन सही निकला या नहीं।
| वर्ष | जन॰ | फ़र॰ | मार्च | अप्रैल | मई | जून | जुल॰ | अग॰ | सित॰ | अक्टू॰ | नव॰ | दिस॰ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
